The Way In Which AZD2014 Might Shock Many Of Us

The uveitis cohort had the shortest first and second DEX implant reinjection intervals (4.7��0.3 months and 3.4��0.4 months, respectively). Concomitant treatments and procedures In the DME, RVO, and uveitis cohorts, repeat DEX implant injections were administered to 44.2%, 50.0%, and 43.5% of study eyes, respectively, and adjunctive treatments and/or procedures were administered to 41.2%, 26.7%, and 78.3% of study eyes, respectively (Table 4). The most common adjunctive intravitreal treatments administered with DEX implants among DME, RVO, and uveitis study eyes were bevacizumab (8.8%, 10.0%, and 13.0%, respectively) and IVTA (20.6%, 13.3%, and 4.3%, respectively). Systemic treatments were primarily administered to patients with a diagnosis of uveitis, with the most common systemic therapy in this group being mycophenolate mofetil (47.8%). Table 4 Medications and procedures used adjunctively with intravitreal dexamethasone implant therapy Few surgical procedures were performed during the study period. Vitrectomy was the most commonly reported procedure in study eyes with DME (11.8%) and vitrectomy with membrane peeling was most prevalent in study eyes with DME (8.8%). Focal/grid laser was most prevalent in study eyes with RVO (10.0%) and DME (5.9%). One eye with uveitis was switched to a fluocinolone acetonide implant (Retisert?, Bausch & Lomb Inc, Rochester, NY, USA) by a clinician who believed a longer-acting intraocular this website steroid was needed. This same eye underwent prophylactic tube-shunt glaucoma surgery at conclusion of surgical placement of the fluocinolone acetonide implant. Efficacy of DEX injections in DME, RVO, and uveitis cohorts The greatest peak mean line gains from baseline after DEX implant injection were observed in study eyes with uveitis (P also observed in subgroups of non-vitrectomized and vitrectomized eyes with uveitis and non-vitrectomized eyes with RVO (Figure 1). For study eyes with DME, average peak gains in lines of vision were not statistically significant compared with baseline for all eyes or for non-vitrectomized and vitrectomized eyes (Figure 1). When analyzed by lens status at baseline, in the DME cohort, a peak mean loss of 0.6��0.6 lines in phakic eyes and a statistically significant peak mean gain of 1.4��0.5 lines (P